THTomoko Horiguchi

Tomoko Horiguchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tomoko Horiguchi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Need for Variant-Specific Splicing Assessment in Developing Antisense Oligonucleotide Therapies for Duchenne Muscular Dystrophy: Lessons from the DMD c.4675−2A>G Variant

    by Aiko Sunami, Tomoko Horiguchi, Atsuko Takeuchi, Yuka Ishikawa, Naoyuki Kataoka, Koichiro Komai, Hisahide Nishio, Masafumi Matsuo

    Duchenne muscular dystrophy is caused by pathogenic variants in the DMD gene. Splice-site variants can generate aberrant transcripts whose consequences cannot always be predicted by the classical reading-frame rule. Here, we characterized the c.4675−2A>G variant at the exon 34 splice acceptor site for the development of an exon-skipping therapy. A minigene analysis demonstrated that c.4675−2A>G activated a cryptic splice acceptor within exon 34 rather than inducing skipping of the entire exon, resulting in deletion of the first 7 nucleotides, a frameshift, and a premature termination codon. To restore the reading frame by promoting skipping of the entire exon 34, we used antisense oligonucleotides (ASOs) targeting distinct splice-regulatory regions. Among the ASO treatments tested, including individual ASOs and ASO combinations, A1&E4&D1 produced the highest exon exclusion and consistently promoted exon 34 skipping across the examined −2A mutant genotypes. A1&E4&D1 consists of ASOs A1, E4, and D1. A1 targeted the cryptic 3′ splice acceptor region, E4 targeted a predicted exonic splicing enhancer region, and D1 targeted the 5′ splice donor region. These findings illustrate a stepwise, variant-directed strategy in which characterization of aberrant splicing guides the design of a tailor-made ASO intervention.